Biotechnology
Roche Buys More Time in $4.3B Offer for Spark Therapeutics
Roche plans to regroup on its $4.3 billion offer to buy Spark Therapeutics after failing to win enough Spark shareholder votes, or receiving U.S. regulatory approval.
3 Promising Small Biotech Stocks to Watch
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
Sangamo Stock Soars on Positive Hemophilia Treatment Trial
The stock surges on 'encouraging' results from a genome-therapy trial for the treatment of a severe type of hemophilia.
Keep Your Eye on the Oncology Sector Among Biotech Stocks
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint
The company's treatment, filgotinib, is being developed with Gilead Sciences.
Amarin Jumps After Diabetes Association Adds Drug to Its 'Must Have' List
The American Diabetes Association adds Amarin's Vascepa drug to its standard of care recommendation list.
Future Brightens for 2 Small Biotech Stocks
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
Biogen Announces $5 Billion Buyback Just Days After Stock Plunge
Biogen's board approves a share buyback program days after revealing a phase III trial of a promising Alzheimer's drug is being shelved.
Thermo Fisher to Buy Gene-Therapy Company Brammer Bio for $1.7 Billion
Thermo Fisher Scientific reaches a deal to buy closely held Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies.
Why I Make a Myriad of Small Biotech Bets
The fact is there are few more complex areas of the market than the small-cap biotech sector. Patience is key.